Mesoblast (NASDAQ:MESO) Shares Pass Above 50-Day Moving Average – Should You Sell?

Shares of Mesoblast Limited (NASDAQ:MESO) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $14.93 and traded as high as $15.77. Mesoblast shares last traded at $15.31, with a volume of 188,306 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mesoblast in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Mesoblast currently has a consensus rating of “Moderate Buy”.

Mesoblast Stock Performance

The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.41 and a current ratio of 1.58. The stock has a fifty day simple moving average of $14.93 and a two-hundred day simple moving average of $15.73. The stock has a market cap of $1.98 billion, a PE ratio of -54.68 and a beta of 2.08.

Institutional Investors Weigh In On Mesoblast

Hedge funds have recently bought and sold shares of the business. Creative Planning bought a new stake in shares of Mesoblast in the second quarter worth $141,000. Quadrant Capital Group LLC acquired a new position in Mesoblast during the 3rd quarter worth $113,000. Raymond James Financial Inc. bought a new stake in shares of Mesoblast in the 2nd quarter worth about $86,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Mesoblast in the 4th quarter worth about $34,000. Finally, Bank of America Corp DE raised its stake in shares of Mesoblast by 608.4% in the 1st quarter. Bank of America Corp DE now owns 100,004 shares of the company’s stock valued at $1,538,000 after purchasing an additional 85,888 shares in the last quarter. Institutional investors and hedge funds own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.